Orchid Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Orchid Pharma Ltd reported a 15.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.5%.
• Its expenses for the quarter were up by 2.2% QoQ and 0.2% YoY.
• The net profit decreased 288.6% QoQ and increased 6.7% YoY.
• The earnings per share (EPS) of Orchid Pharma Ltd stood at 4.69 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Orchid Pharma Ltd is a pharmaceutical company engaged primarily in the development, manufacture, and marketing of a wide range of bulk actives, formulations, and nutraceuticals. The company operates in the healthcare sector, focusing on producing generic drugs and specialty pharmaceuticals. While specific recent developments are not detailed in the available data, companies in this industry often engage in research and development to expand their product offerings and adapt to regulatory changes. Orchid Pharma Ltd serves both domestic and international markets, with a significant portion of its revenue likely stemming from exports.

Revenue

In Q4FY26, Orchid Pharma Ltd reported a total income of ₹244.95 crores. This represents a quarter-over-quarter (QoQ) increase of 15.1% compared to Q3FY26, where the total income was ₹212.88 crores. Year-over-year (YoY), the total income showed a modest increase of 1.5% from Q4FY25, which recorded ₹241.38 crores. The revenue growth indicates an upward trend in the company's financial performance over the quarters, reflecting its ability to generate increased sales or services revenue.

Profitability

Orchid Pharma Ltd's profitability demonstrated significant improvement in Q4FY26. The company reported a profit before tax (PBT) of ₹22.79 crores, a substantial recovery from a loss of ₹12.15 crores in Q3FY26. This marks a dramatic QoQ change of -287.6%. Compared to Q4FY25, where the PBT was ₹19.09 crores, there was a YoY increase of 19.4%. Consequently, the profit after tax (PAT) for Q4FY26 was ₹23.78 crores, contrasting sharply with the loss of ₹12.61 crores in Q3FY26. The YoY growth in PAT from ₹22.29 crores in Q4FY25 is 6.7%. Earnings per share (EPS) followed a similar trend, increasing to ₹4.69 in Q4FY26 from ₹4.40 in Q4FY25, reflecting a YoY rise of 6.6%.

Operating Metrics

Total expenses for Orchid Pharma Ltd in Q4FY26 were ₹222.70 crores, showing a slight QoQ increase of 2.2% from ₹217.91 crores in Q3FY26. The YoY comparison indicates a minimal rise of 0.2% from ₹222.29 crores in Q4FY25. The company's tax expense was recorded at ₹0.00 crores in Q4FY26, consistent with Q3FY26, indicating no tax liability for these periods. In Q4FY25, the tax was noted as -₹0.04 crores, suggesting a tax adjustment in that period. The absence of tax liabilities in the recent quarters could be a result of accumulated losses or tax provisions from previous periods, although specific details are not provided.